# FRα in ovarian cancer

1 EU-approved indication in ovarian cancer needs a FRα result: mirvetuximab soravtansine (2nd line).

## Approved indications

### FRα-positive

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Mirvetuximab soravtansine](https://oncolabels.com/drugs/mirvetuximab-soravtansine) (Elahere) | FRα FRα-positive | Monotherapy | 2nd line | High-grade serous only; After 1 to 3 prior systemic treatment regimens; Platinum-resistant |

## Label wording

- **Mirvetuximab soravtansine** (Elahere), Ovarian cancer, 2nd line: “ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens (see section 4.2).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/ovarian-cancer/fr-alpha